MeSH term
Frequency | Condition_Probility | *Cleavage Stage, Ovum | 2 | 1.0 |
Embryo Transfer/*standards | 2 | 1.0 |
Female | 34 | 0.0 |
Humans | 104 | 0.0 |
Meta-Analysis | 2 | 1.0 |
Pregnancy | 4 | 0.0 |
Pregnancy Outcome | 2 | 0.0 |
Pregnancy Rate | 2 | 1.0 |
Pregnancy, Multiple | 2 | 1.0 |
Randomized Controlled Trials | 2 | 0.0 |
Review Literature | 2 | 1.0 |
Cell Differentiation/*physiology | 4 | 1.0 |
Adult | 21 | 0.0 |
Male | 28 | 0.0 |
Middle Aged | 22 | 0.0 |
Reference Values | 2 | 0.0 |
Animals | 47 | 0.0 |
Aged | 25 | 0.0 |
Comparative Study | 20 | 0.0 |
Homeodomain Proteins/*metabolism | 15 | 11.0 |
Aged, 80 and over | 11 | 0.0 |
Barrett Esophagus/metabolism/*pathology | 3 | 37.0 |
Biological Markers/analysis | 3 | 0.0 |
Homeodomain Proteins/*analysis/genetics | 3 | 100.0 |
Immunohistochemistry/methods | 5 | 0.0 |
RNA, Messenger/analysis | 5 | 0.0 |
Research Support, Non-U.S. Gov't | 67 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 17 | 0.0 |
Statistics, Nonparametric | 2 | 0.0 |
Adolescent | 2 | 0.0 |
Immunohistochemistry | 28 | 0.0 |
Genotype | 2 | 0.0 |
Mice | 33 | 0.0 |
Mice, Knockout | 5 | 0.0 |
Morphogenesis | 2 | 0.0 |
Polymerase Chain Reaction | 6 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 24 | 0.0 |
Caco-2 Cells | 12 | 3.0 |
Cell Line | 11 | 0.0 |
HT29 Cells | 4 | 2.0 |
Promoter Regions (Genetics) | 12 | 0.0 |
Rats | 7 | 0.0 |
Trans-Activation (Genetics) | 5 | 0.0 |
*Trans-Activators | 5 | 0.0 |
Transfection | 14 | 0.0 |
3T3 Cells | 4 | 0.0 |
Base Sequence | 16 | 0.0 |
Binding Sites | 6 | 0.0 |
Blotting, Northern | 7 | 0.0 |
Blotting, Western | 4 | 0.0 |
Cell Nucleus/metabolism | 4 | 0.0 |
Cloning, Molecular | 6 | 0.0 |
DNA Mutational Analysis | 4 | 0.0 |
*DNA-Binding Proteins | 5 | 0.0 |
Gene Deletion | 3 | 0.0 |
*Gene Expression Regulation, Neoplastic | 6 | 0.0 |
Genes, Reporter | 6 | 0.0 |
Homeodomain Proteins/metabolism | 5 | 5.0 |
Intestines/metabolism | 4 | 3.0 |
Luciferases/metabolism | 4 | 0.0 |
Molecular Sequence Data | 17 | 0.0 |
*Nuclear Proteins | 5 | 0.0 |
*Promoter Regions (Genetics) | 4 | 0.0 |
Protein Binding | 6 | 0.0 |
Protein Structure, Tertiary | 5 | 0.0 |
RNA/metabolism | 2 | 0.0 |
Tissue Distribution | 3 | 0.0 |
Transcription Factors/*metabolism | 4 | 0.0 |
Down-Regulation | 6 | 0.0 |
Homeodomain Proteins/*genetics/metabolism | 7 | 8.0 |
RNA, Messenger/metabolism | 5 | 0.0 |
Disease Progression | 4 | 0.0 |
Gastric Mucosa/metabolism/*pathology | 2 | 20.0 |
Gene Expression | 6 | 0.0 |
Intestinal Mucosa/metabolism/*pathology | 3 | 27.0 |
Metaplasia | 7 | 7.0 |
Cell Differentiation | 13 | 0.0 |
DNA Primers/chemistry | 2 | 0.0 |
Gastrointestinal Neoplasms/*metabolism/pathology | 2 | 13.0 |
Neoplasm Proteins/genetics/metabolism | 2 | 1.0 |
Trans-Activators/genetics | 2 | 0.0 |
*Avian Proteins | 14 | 14.0 |
Colorectal Neoplasms/*pathology | 2 | 3.0 |
Diagnosis, Differential | 2 | 0.0 |
Homeodomain Proteins/*biosynthesis | 8 | 28.0 |
Tumor Markers, Biological/analysis | 2 | 0.0 |
Homeodomain Proteins/genetics/*physiology | 3 | 5.0 |
Metaplasia/metabolism | 3 | 23.0 |
Mice, Transgenic | 4 | 0.0 |
Neoplasm Proteins/metabolism | 3 | 0.0 |
Stomach Neoplasms/*metabolism/pathology | 2 | 3.0 |
COS Cells | 3 | 0.0 |
Tumor Cells, Cultured | 13 | 0.0 |
Adenocarcinoma/genetics/metabolism/pathology | 2 | 6.0 |
Loss of Heterozygosity | 4 | 0.0 |
Mutation | 6 | 0.0 |
Amino Acid Sequence | 10 | 0.0 |
Bromodeoxyuridine/diagnostic use | 2 | 9.0 |
Drosophila | 2 | 0.0 |
Electrophoretic Mobility Shift Assay | 3 | 0.0 |
Sequence Homology, Amino Acid | 4 | 0.0 |
Mice, Inbred C57BL | 4 | 0.0 |
Mice, Nude | 2 | 0.0 |
Colon/cytology/metabolism | 2 | 22.0 |
Phosphorylation | 2 | 0.0 |
Hela Cells | 3 | 0.0 |
Homeodomain Proteins/genetics/*metabolism | 10 | 6.0 |
Trans-Activators/genetics/*metabolism | 2 | 0.0 |
*Genes, Homeobox | 7 | 3.0 |
Homeodomain Proteins/genetics | 2 | 0.0 |
Colonic Neoplasms/*genetics | 2 | 2.0 |
DNA-Binding Proteins/*genetics | 2 | 0.0 |
Transcription Factors/*genetics | 2 | 0.0 |
*Gene Expression Regulation, Enzymologic | 4 | 0.0 |
In Situ Hybridization | 2 | 0.0 |
Promoter Regions (Genetics)/genetics | 3 | 0.0 |
RNA, Messenger/genetics/metabolism | 4 | 0.0 |
Response Elements/genetics | 2 | 1.0 |
Cell Division | 7 | 0.0 |
Gene Expression Regulation | 3 | 0.0 |
Epithelium/metabolism/pathology | 3 | 4.0 |
Colorectal Neoplasms/*genetics | 3 | 1.0 |
DNA-Binding Proteins/genetics | 2 | 0.0 |
Exons | 2 | 0.0 |
Homeodomain Proteins/*genetics | 13 | 2.0 |
Mutation, Missense | 2 | 0.0 |
Polymorphism, Genetic | 3 | 0.0 |
Polymorphism, Single-Stranded Conformational | 3 | 0.0 |
Cell Survival | 2 | 0.0 |
Enzyme Inhibitors/pharmacology | 2 | 0.0 |
Fetus | 2 | 0.0 |
Alleles | 3 | 0.0 |
Cohort Studies | 2 | 0.0 |
RNA, Neoplasm/genetics/metabolism | 2 | 1.0 |
Sequence Analysis, DNA | 2 | 0.0 |
Nuclear Proteins/metabolism | 2 | 0.0 |
Genes, Homeobox/*genetics | 2 | 3.0 |
Hydrogen-Ion Concentration | 3 | 0.0 |
Cell Transformation, Neoplastic/genetics | 2 | 0.0 |
Homeodomain Proteins/*biosynthesis/genetics | 3 | 11.0 |
Immunoenzyme Techniques | 5 | 0.0 |
DNA Footprinting | 2 | 0.0 |
Homeodomain Proteins/metabolism/*physiology | 3 | 27.0 |
Transcription, Genetic | 8 | 0.0 |
Immunophenotyping | 2 | 0.0 |
Keratin/metabolism | 2 | 1.0 |
Mucins/*metabolism | 2 | 2.0 |
Tumor Markers, Biological/metabolism | 3 | 0.0 |
Cell Line, Tumor | 5 | 0.0 |
Colonic Neoplasms/metabolism | 2 | 3.0 |
Cytoskeletal Proteins/metabolism | 2 | 0.0 |
Epithelium/metabolism | 2 | 0.0 |
Gene Expression Regulation, Neoplastic | 6 | 0.0 |
Microscopy, Fluorescence | 3 | 0.0 |
Phenotype | 8 | 0.0 |
Signal Transduction | 3 | 0.0 |
Trans-Activators/metabolism | 3 | 0.0 |
Transcription Factors/genetics/*metabolism | 2 | 0.0 |
In Situ Hybridization, Fluorescence | 4 | 0.0 |
Models, Genetic | 2 | 0.0 |
Trans-Activators/*metabolism | 2 | 0.0 |
Translocation, Genetic/*genetics | 2 | 0.0 |
Tumor Markers, Biological/*analysis | 5 | 0.0 |
Dose-Response Relationship, Drug | 2 | 0.0 |
*Transcription, Genetic | 4 | 0.0 |
Chromosome Banding | 2 | 0.0 |
*Chromosome Mapping | 4 | 0.0 |
Chromosomes, Human, Pair 13 | 2 | 1.0 |
Helix-Loop-Helix Motifs | 2 | 0.0 |
Mice/*genetics | 2 | 0.0 |
Pancreas/metabolism | 2 | 2.0 |
Transcription Factors/chemistry/*genetics | 2 | 2.0 |
Prognosis | 3 | 0.0 |
*Mutation | 2 | 0.0 |
Colonic Neoplasms/metabolism/*pathology | 2 | 8.0 |
Stomach Neoplasms/metabolism/*pathology | 2 | 6.0 |
*Gene Expression Regulation | 3 | 0.0 |
Oligonucleotide Array Sequence Analysis | 2 | 0.0 |
Plasmids/metabolism | 2 | 0.0 |
DNA-Binding Proteins/*metabolism | 2 | 0.0 |
Leukemia, Myelocytic, Acute/*genetics/pathology | 2 | 6.0 |
Gastric Mucosa/*metabolism/pathology | 2 | 15.0 |
Homeodomain Proteins/*analysis | 2 | 100.0 |
DNA Primers | 4 | 0.0 |
Up-Regulation | 3 | 0.0 |
Chromosomes, Human, Pair 13/genetics | 2 | 3.0 |
Hamsters | 2 | 0.0 |
Adenocarcinoma/metabolism/*pathology | 2 | 3.0 |
Transcription Factors/metabolism | 2 | 0.0 |
Adenocarcinoma/metabolism/pathology | 2 | 3.0 |
Neoplasm Metastasis | 2 | 0.0 |
Sensitivity and Specificity | 3 | 0.0 |
Disease Models, Animal | 2 | 0.0 |
Species Specificity | 2 | 0.0 |
Colonic Neoplasms | 2 | 1.0 |
English Abstract | 2 | 0.0 |
DNA, Complementary/genetics | 2 | 0.0 |
Mucins/*genetics/metabolism | 2 | 7.0 |
Plasmids/genetics | 2 | 0.0 |
Cells, Cultured | 3 | 0.0 |
Transcription Factors/*analysis | 2 | 3.0 |
Tumor Markers, Biological/*analysis/genetics | 2 | 5.0 |
Metaplasia/metabolism/pathology | 2 | 25.0 |
Multivariate Analysis | 2 | 0.0 |
Time Factors | 3 | 0.0 |
